Reviewing Panbela Therapeutics (OTCMKTS:PBLA) & MusclePharm (OTCMKTS:MSLP)

Insider & Institutional Ownership

15.5% of MusclePharm shares are held by institutional investors. Comparatively, 4.4% of Panbela Therapeutics shares are held by institutional investors. 60.7% of MusclePharm shares are held by company insiders. Comparatively, 0.0% of Panbela Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares MusclePharm and Panbela Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MusclePharm	$50.04 million	0.00	-$12.87 million	($0.58)	N/A
Panbela Therapeutics	N/A	N/A	-$25.26 million	($71.13)	0.00

MusclePharm has higher revenue and earnings than Panbela Therapeutics. Panbela Therapeutics is trading at a lower price-to-earnings ratio than MusclePharm, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

MusclePharm has a beta of -0.07, indicating that its stock price is 107% less volatile than the S&P 500. Comparatively, Panbela Therapeutics has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.

Profitability

This table compares MusclePharm and Panbela Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MusclePharm	-38.51%	N/A	-169.56%
Panbela Therapeutics	N/A	N/A	N/A

Summary

MusclePharm beats Panbela Therapeutics on 5 of the 9 factors compared between the two stocks.

About MusclePharm

MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.

About Panbela Therapeutics

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.